Synthorx Inc

Synthorx is a biotechnology company using ground-breaking synthetic biology starting with our novel DNA base pair to discover and develop new protein therapeutics.  The company uses new building blocks to create proteins that impart specificity not possible with native proteins. The result is treatments with improved efficacy, better safety, and better convenience for patients. Utilizing proprietary engineered organisms we have the ability to manufacture these improved proteins with high fidelity and the required yield for drug discovery and development. This unique platform expands the chemical and structural repertoire of protein therapeutics and uncovers new ways to modulate pharmacological properties of biologics, not possible with other technologies. The company was founded by Avalon Ventures based on important discoveries in Dr. Floyd Romesberg’s lab at The Scripps Research Institute in La Jolla, Calif. These discoveries include research published by the Romesberg lab in Nature, describing the first example of in vivo replication of a synthetic DNA base pair and the development of a semi-synthetic organism (read more here). Synthorx has the exclusive rights to this synthetic biology technology from The Scripps Research Institute. Investors include Avalon Ventures, Correlation Ventures, Medicxi, Orbimed, Osage University Partners, and RA Capital Management.

Winnebago

Both have seen sales slump thanks to higher interest rates and slower consumer spending. Winnebago's focus on the luxury RV market has helped it maintain higher profitability.

Better Buy for the RV Rebound: Winnebago or Thor?

Sales are still rising even as prices soar.

The RV Market Is Booming, and That's Great News for This Stock

Jack in the Box

GuruFocus' summary page provides rankings for individual securities in a number of different areas. In each category, the company is compared both its industry as well as its 10-year history.

2 Companies Scoring High on GuruFocus' Valuation Rank

Synthorx, Inc. (THOR) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

Moving Average Crossover Alert: Synthorx

ArQule

Merck

Spark Therapeutics

Roche Holding AG

Sanofi

Week Begins with Biotech Mergers

Sanofi and the clinical-stage biotech Synthorx announced a $2.5 billion buyout agreement Monday morning.

Why Synthorx Stock Is Soaring Today

Large-cap pharmaceutical companies are putting their assets to work in the biotech space, particularly in cancer treatment (oncology).

Merger Monday, Biotech Edition: MRK, SNY, ARQL, THOR & More

Synthorx, Inc. (NASDAQ: THOR) shares are trading sharply higher after the company announced it would be acquired by Sanofi (NYSE: SNY) for $68 per share in cash, which represents an aggregate equity value of $2.5 billion.

Synthorx To Be Acquired By Sanofi For $2.5B

French pharma giant Sanofi agreed to buy Synthorx Inc. for $2.5 billion, more than double the U.S.

Sanofi To Buy Synthorx For $2.5 Billion To Expand In Cancer

France's Sanofi on Monday agreed to buy California-headquartered biotechnology firm Synthorx in a cash deal worth about $2.5 billion as it steps up a push in the lucrative field of cancer drugs under its new chief executive.

France's Sanofi to buy biotech firm Synthorx for $2.5 billion

France's Sanofi  said on Monday it had agreed to buy Synthorx in a cash deal worth around $2.5 billion as it seeks to beef up its immuno-oncology pipeline.

France's Sanofi to buy Synthorx for $2.5 billion

As of late, it has definitely been a great time to be an investor Synthorx.

Will Synthorx Continue to Surge Higher?

SAN DIEGO, Oct.  29, 2019  (GLOBE NEWSWIRE) -- Synthorx, Inc. (NASDAQ: THOR), a clinical-stage biotechnology company developing optimized therapeutics for cancer and autoimmune disorders, today announced the presentation of three  posters at the upcoming Society for Immunotherapy of Cancer (SITC) 34th Annual Meeting in National Harbor, MD, from November 6-10, 2019. These posters will highlight the company’s lead product candidate THOR-707 and two of its other Synthorin™ cytokines for immuno-oncology.

Synthorx to Present at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

Apple

Bristol-Myers

Disney

Apple, Disney, Thor Industries and Bristol-Myers Squibb were our top stock trades from Monday. Here's a look at the charts.

4 Top Stock Trades for Tuesday: AAPL, DIS, BMY & THOR

SAN DIEGO, Sept.  23, 2019  (GLOBE NEWSWIRE) -- Synthorx, Inc. (NASDAQ: THOR), a clinical-stage biotechnology company developing optimized therapeutics for cancer and autoimmune disorders, today announced that preclinical data for immuno-oncology product candidate, THOR-707, will be presented at the upcoming European Society for Medical Oncology (ESMO) 2019 Congress in Barcelona, Spain, from September 27 through October 1, 2019.

Synthorx to Present at the European Society for Medical Oncology (ESMO) 2019 Congress

First-of-its-Kind Genetic Alphabet Platform Used to Design Synthorin for Autoimmune Indications First-of-its-Kind Genetic Alphabet Platform Used to Design Synthorin for Autoimmune Indications

Synthorx to Present at the 2019 World Congress of Inflammation

SAN DIEGO, Aug.  29, 2019  (GLOBE NEWSWIRE) -- Synthorx, Inc. (NASDAQ: THOR), a clinical-stage biotechnology company developing optimized therapeutics for cancer and autoimmune disorders, today announced the Company will present at the H.C. Wainwright 21st Annual Global Investment Conference on Monday, September 9 at 10:25 a.m. ET in New York, NY.

Synthorx to Present at H.C. Wainwright 21st Annual Global Investment Conference

As of late, it has definitely been a great time to be an investor in Synthorx.

Synthorx's Shares March Higher, Can It Continue?

Tanger Factory Outlet Centers

Zuora

Wall Street has a bad habit of ignoring investment ideas because they are long term in nature.

News for Synthorx Inc Stock (THOR)